Aimfinity Investment Corp. I disclosed that its sponsor’s designee, I‑Fa Chang, deposited $500 into the SPAC’s trust account on both March 28, 2026 and April 28, 2026, triggering one‑month extensions of the deadline to complete its initial business combination, first to April 28, 2026 and then to May 28, 2026.
These were the sixth and seventh of up to nine permitted monthly extensions under the current charter, each requiring a $500 deposit. In connection with these and prior loans, the company issued an unsecured promissory note dated May 5, 2026 to Mr. Chang with a principal amount of up to $2,000, of which $1,000 had been drawn as of May 6, 2026.
The note bears no regular interest, with default interest tied to the prevailing short‑term U.S. Treasury Bill rate, and is repayable upon completion of Aimfinity’s initial business combination or liquidation. Under an exchange agreement related to Aimfinity’s planned business combination with Docter Inc., any outstanding balance on the note at closing will automatically convert into PubCo ordinary shares at a conversion price of $10.00 per share. The note was issued under a private offering exemption from registration.
Aimfinity Investment Corp. I disclosed that its sponsor’s designee, I‑Fa Chang, deposited $500 into the SPAC’s trust account on both March 28, 2026 and April 28, 2026, triggering one‑month extensions of the deadline to complete its initial business combination, first to April 28, 2026 and then to May 28, 2026.
These were the sixth and seventh of up to nine permitted monthly extensions under the current charter, each requiring a $500 deposit. In connection with these and prior loans, the company issued an unsecured promissory note dated May 5, 2026 to Mr. Chang with a principal amount of up to $2,000, of which $1,000 had been drawn as of May 6, 2026.
The note bears no regular interest, with default interest tied to the prevailing short‑term U.S. Treasury Bill rate, and is repayable upon completion of Aimfinity’s initial business combination or liquidation. Under an exchange agreement related to Aimfinity’s planned business combination with Docter Inc., any outstanding balance on the note at closing will automatically convert into PubCo ordinary shares at a conversion price of $10.00 per share. The note was issued under a private offering exemption from registration.
Aimfinity Investment Corp. I entered into a small financing arrangement to extend the deadline for completing its initial business combination. On February 28, 2026, the company issued an unsecured promissory note for $500 to I-Fa Chang, designated by the sponsor, and deposited the same amount into its trust account as a monthly extension payment.
This fifth of up to nine allowed extensions moves the business combination deadline from February 28, 2026 to March 28, 2026. Under an existing exchange agreement, the note balance will automatically convert into PubCo ordinary shares at $10.00 per share upon closing the proposed business combination with Docter Inc., unless repaid earlier. The note was issued under a private placement exemption, and the company also released a press statement announcing the extension.
Aimfinity Investment Corp. I entered into a small financing arrangement to extend the deadline for completing its initial business combination. On February 28, 2026, the company issued an unsecured promissory note for $500 to I-Fa Chang, designated by the sponsor, and deposited the same amount into its trust account as a monthly extension payment.
This fifth of up to nine allowed extensions moves the business combination deadline from February 28, 2026 to March 28, 2026. Under an existing exchange agreement, the note balance will automatically convert into PubCo ordinary shares at $10.00 per share upon closing the proposed business combination with Docter Inc., unless repaid earlier. The note was issued under a private placement exemption, and the company also released a press statement announcing the extension.
Aimfinity Investment Corp. I received an amended Schedule 13G/A showing that a group of Harraden Circle investment entities and Frederick V. Fortmiller, Jr. now report beneficial ownership of 0 shares, or 0%, of the Class A common stock as of 12/31/2025.
The filing states this is an exit filing, confirming that these reporting persons have ceased to be beneficial owners of more than five percent of Aimfinity’s Class A shares and no longer hold voting or dispositive power over the stock.
Aimfinity Investment Corp. I received an amended Schedule 13G/A showing that a group of Harraden Circle investment entities and Frederick V. Fortmiller, Jr. now report beneficial ownership of 0 shares, or 0%, of the Class A common stock as of 12/31/2025.
The filing states this is an exit filing, confirming that these reporting persons have ceased to be beneficial owners of more than five percent of Aimfinity’s Class A shares and no longer hold voting or dispositive power over the stock.
Aimfinity Investment Corp. I disclosed that it issued an unsecured promissory note for $500 to I-Fa Chang, the sponsor’s designee, to fund a monthly extension payment into the trust account for public shareholders. This payment extends the deadline to complete its initial business combination by one month, from January 28, 2026 to February 28, 2026.
The new extension is the fourth of up to nine one‑month extensions authorized under a prior charter amendment, each requiring a $500 deposit into the trust account. Upon closing of the proposed business combination with Docter Inc., any unpaid balance of the note will automatically convert into PubCo ordinary shares at a conversion price of $10.00 per share. The note was issued under a Section 4(a)(2) exemption, and the company also furnished a press release announcing the extension.
Aimfinity Investment Corp. I disclosed that it issued a $500 unsecured promissory note to I-Fa Chang, a manager of its sponsor’s LLC, to fund a monthly extension payment into the SPAC trust account. This payment allows Aimfinity to extend the deadline to complete its initial business combination by one month, from December 28, 2025 to January 28, 2026, representing the third of up to nine one‑month extensions authorized under a prior charter amendment.
Under an existing exchange agreement, the note’s outstanding balance will automatically convert into PubCo ordinary shares at $10.00 per share if the business combination between Aimfinity and Docter Inc. closes, unless repaid earlier. The note was issued under a private offering exemption from registration, and the company also furnished a press release announcing the new extension while reiterating extensive forward‑looking statement and transaction risk disclosures.
Aimfinity Investment Corp. I disclosed that it issued a $500 unsecured promissory note to I-Fa Chang, a manager of its sponsor’s LLC, to fund a monthly extension payment into the SPAC trust account. This payment allows Aimfinity to extend the deadline to complete its initial business combination by one month, from December 28, 2025 to January 28, 2026, representing the third of up to nine one‑month extensions authorized under a prior charter amendment.
Under an existing exchange agreement, the note’s outstanding balance will automatically convert into PubCo ordinary shares at $10.00 per share if the business combination between Aimfinity and Docter Inc. closes, unless repaid earlier. The note was issued under a private offering exemption from registration, and the company also furnished a press release announcing the new extension while reiterating extensive forward‑looking statement and transaction risk disclosures.
Aimfinity Investment Corp. I, a SPAC, reported net income of $117,673 for the nine months ended September 30, 2025, driven by $630,505 of interest on cash and investments in its trust account, which more than offset $512,832 of formation and operating costs. The trust account balance fell to $14,294,569 from $36,940,228 at year-end 2024, mainly after redeeming 1,996,522 Class A shares for a total of $23,778,577.
Outside the trust, cash was only $3,517 with a working capital deficit of $2,785,815, and management concluded that these conditions, together with the limited time left to complete a merger, raise substantial doubt about the company’s ability to continue as a going concern. The SPAC continues to pursue a business combination with Docter Inc., has amended its charter multiple times to extend its deadline (with deposits totaling $1,808,413 into the trust for extensions), and has converted $1,500,000 of sponsor loans into 150,000 private units while restructuring deferred underwriting fees into a mix of cash and stock payable at closing.
Aimfinity Investment Corp. I, a SPAC, reported net income of $117,673 for the nine months ended September 30, 2025, driven by $630,505 of interest on cash and investments in its trust account, which more than offset $512,832 of formation and operating costs. The trust account balance fell to $14,294,569 from $36,940,228 at year-end 2024, mainly after redeeming 1,996,522 Class A shares for a total of $23,778,577.
Outside the trust, cash was only $3,517 with a working capital deficit of $2,785,815, and management concluded that these conditions, together with the limited time left to complete a merger, raise substantial doubt about the company’s ability to continue as a going concern. The SPAC continues to pursue a business combination with Docter Inc., has amended its charter multiple times to extend its deadline (with deposits totaling $1,808,413 into the trust for extensions), and has converted $1,500,000 of sponsor loans into 150,000 private units while restructuring deferred underwriting fees into a mix of cash and stock payable at closing.
Aimfinity Investment Corp. I disclosed that shareholders approved changes to its charter that let the company extend the deadline to complete its initial business combination in one-month increments, up to nine months, to July 28, 2026, by depositing $500 into its trust account for each extension. The charter was also amended to remove the requirement that any business combination leave the company with at least $5,000,001 of net tangible assets.
On November 28, 2025, Aimfinity issued an unsecured promissory note for $500 to I-Fa Chang, designated by the sponsor, to fund the first new monthly extension, moving the transaction deadline from November 28, 2025 to December 28, 2025. Upon closing of its proposed business combination with Docter Inc., any unpaid balance of this note will automatically convert into PubCo ordinary shares at a price of $10.00 per share.
Aimfinity Investment Corp. I disclosed that shareholders approved changes to its charter that let the company extend the deadline to complete its initial business combination in one-month increments, up to nine months, to July 28, 2026, by depositing $500 into its trust account for each extension. The charter was also amended to remove the requirement that any business combination leave the company with at least $5,000,001 of net tangible assets.
On November 28, 2025, Aimfinity issued an unsecured promissory note for $500 to I-Fa Chang, designated by the sponsor, to fund the first new monthly extension, moving the transaction deadline from November 28, 2025 to December 28, 2025. Upon closing of its proposed business combination with Docter Inc., any unpaid balance of this note will automatically convert into PubCo ordinary shares at a price of $10.00 per share.
Aimfinity Investment Corp. I reported shareholder approval of an amendment allowing extensions of its business combination deadline to October 28, 2025, with up to nine one‑month extensions to July 28, 2026 by depositing $500 per month. The company elected to extend to November 28, 2025 and deposited $500 into its trust account.
The company was informed that 572,989 Class A ordinary shares were tendered for redemption in connection with the extension process. In addition, 503,472 Class A ordinary shares remain subject to redemption upon the closing of the proposed business combination with Docter Inc., based on prior requests. The business combination had previously been approved at the March 27, 2025 meeting.
Aimfinity’s securities trade over-the-counter: units (AIMUF), new units (AIMTF), and Class 1 redeemable warrants (AIMWF), each warrant exercisable for one Class A ordinary share at an exercise price of $11.50.
Aimfinity Investment Corp. I reported shareholder approval of an amendment allowing extensions of its business combination deadline to October 28, 2025, with up to nine one‑month extensions to July 28, 2026 by depositing $500 per month. The company elected to extend to November 28, 2025 and deposited $500 into its trust account.
The company was informed that 572,989 Class A ordinary shares were tendered for redemption in connection with the extension process. In addition, 503,472 Class A ordinary shares remain subject to redemption upon the closing of the proposed business combination with Docter Inc., based on prior requests. The business combination had previously been approved at the March 27, 2025 meeting.
Aimfinity’s securities trade over-the-counter: units (AIMUF), new units (AIMTF), and Class 1 redeemable warrants (AIMWF), each warrant exercisable for one Class A ordinary share at an exercise price of $11.50.